Calendar of Events

Registration is required.

Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.

At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.

Presenters
Monique Perron, ScD
Acting Branch Chief, Risk Assessment Branch IV
US EPA, OPP, HED

Event Information: NAMSS Webinar: From Nanomaterials to Advanced Materials: A Health and Safety Perspective

Date and time: Thursday, January 30, 2020 1:00 pm
Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour

Description:
Advances in nanoscale science have resulted in materials that are more active, more efficient, and more versatile in their commercial applications. A key outgrowth has been the development and deployment of ‘Advanced Materials’. These materials are chemically and biologically more active and more efficient for the specific functions for which they are designed. Advanced materials are combining with the development of new manufacturing technologies, such as additive manufacturing, 3D printing, and engineered/synthetic biology, to give us a vision of the new materials, processes, and products that make up ‘21st Century Manufacturing’. The challenge for the EHS professional is to remain current on the issues of potential health hazards, the degree to which these materials are being introduced into new manufacturing technologies, and the way they are used and incorporated into products. The types of risk assessment and management approaches needed to support safe, responsible, and sustainable commercialization of nano- and advanced-material-enabled products can be challenging, but a lot of progress has been made in the past 10 years. Many of the lessons learned with nanotechnology will have direct re-application opportunities in the rapidly emerging world of advanced materials and the 21st Century manufacturing environment.

Speaker
Dr. Charles Geraci
Associate Director of Emerging Technologies
National Institute for Occupational Safety and Health (NIOSH/CDC)

Registration is required

The US Food and Drug Administration (FDA) is hosting a public meeting on February 4, 2020 from 8:30am - 5:00pm EST at the FDA White Oak Campus, Great Room (10903 New Hampshire Avenue, Silver Spring, MD 20993) to discuss testing methods for asbestos in talc and cosmetic products containing talc. Webcast will be avaiable.

Public meeting attendees are encouraged to register online to attend the meeting in person and via live webcast.

Event Information: CTSS Webinar: US FDA Experience in the Regulatory Application of (Q)SAR Modeling

Date and time: Wednesday, February 5, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour

The US Food and Drug Administration (FDA) actively promotes and supports research into state-of-the-art computational toxicology approaches including (quantitative) structure-activity relationship, also known as(Q)SAR, modeling for regulatory decision-making. Within FDA’s Center for Drug Evaluation and Research, a significant focus of this research is on the safety assessment of drug impurities under the ICH M7 guideline, where a (Q)SAR prediction can be used as an alternative to empirical testing to assess mutagenic potential. The successful implementation of the ICH M7 guideline has led to the development of best practices for the conduct of (Q)SAR analyses, evaluation of model outputs, and submission of (Q)SAR data to regulators. Building on this success, new opportunities for the regulatory application of (Q)SARs are being explored for other endpoints including carcinogenicity and endocrine disruption, as well as for other components of FDA-regulated products beyond impurities.

This presentation will provide an in-depth look at current regulatory practice and expectations for the use of (Q)SAR models under ICH M7, as well as highlight emerging applications of the methodology to chemical entities and endpoints of regulatory importance to FDA.

Speaker
Naomi Kruhlak, BS, PhD
US Food & Drug Administration, Center for Drug Evaluation & Research

Registration is required.

Attendee Link

Donna Voorhees, PhD
Director of Energy Research
Health Effects Institute (HEI)
Boston, MA

Onshore development of oil and natural gas from unconventional resources (unconventional oil and gas development, abbreviated in this presentation as “UOGD”) has expanded rapidly in the United States during the last decade and, along with it, concern about its potential health effects. While UOGD shares many attributes of conventional oil and gas development that has been around since the 1800s, it is occurring in locations and at a scale not always familiar to those living nearby. This presentation will summarize methodologic challenges and opportunities in understanding the potential for health effects, especially through risk-based analyses.

Beginning in 2012, academic scientists and public health authorities published human health risk assessments and risk-based screening assessments that combined information about potential UOGD-related chemical concentrations with relevant toxicity information to predict risk to communities in Colorado, North Dakota, Pennsylvania and the broader Marcellus region, Texas, and Wyoming. Nearly all assessments quantified risk to community members associated with potential exposure to UOGD-related chemicals in air, but several assessed risks involving water. Assessments varied in their complexity, from screening-level comparisons of chemical concentrations, to health-based benchmarks, to more involved assessments measuring potential exposure specific to a population, including control for baseline, or background, conditions. Conclusions differed among the risk assessments and were subject to important sources of uncertainty about exposure and toxicity and the judgments made by investigators to address them. The body of work also was limited in its relevance to operations, regions, and populations beyond those that were the subject of each assessment. Future investigators must grapple with the extensive temporal and spatial variability in potential exposure as a function of numerous factors (e.g., differences in regulations, environmental conditions, and practices among UOGD operators), the uncertainties about potential exposure (e.g., when and where will operations happen, the identity of chemicals being used, the efficacy of noise mitigation), and the lack of toxicity information for some chemicals associated with UOGD operations.

Teleconference information

It takes immense pleasure to invite you to attend 4th International Conference on Chronic Diseases (Chronic Diseases 2020) scheduled to be held in Paris, France during February 17-18, 2020.
Chronic Diseases 2020 is a global event focusing on the immense knowledge and major advances in the rapidly emerging fields of chronic diseases by attracting experts and professionals across the universe.

Visit: https://chronicdiseases.cmesociety.com/

Oxford Global is proud to present for the 15th year our flagship Biomarkers Series UK, 18 – 20 February 2020, Manchester, UK. This year promises to be the most exciting Biomarkers Series to date, with a host of new features alongside the popular programme to ensure you gain vital updates on the latest biomarker initiatives and technologies.

Featuring the following interactive streams:

New for 2020, we are pleased to announce the following features:

- The Inaugural Genomic Markers Congress: Two dedicated streams on the integration of genomic markers into drug development to enable precision medicine
- A pre-event focus day: Deep-dive sessions in the morning to provide insights into key therapeutic areas from leading experts and end-user workshops in the afternoon to showcase key platforms to incorporate in your workflow. Spaces are limited, so sign-up early to avoid disappointment
- Our Day 1 workshop on Biomarker Qualification: Technical Validation and Regulatory Aspects
- Our Day 2 workshops on Data Analysis and Bioinformatics and Genomic Biobanking to Facilitate Precision Medicine

On Tuesday February 18, 2020 at 7:00 am (ends Thursday February 20, 2020 at 7:00 pm)

Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.

WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director

Registration is required.

For Registration: http://stemcell.alliedacademies.com/registration

Contact Details:

Leon Bezos,
Program Director,
Stem Cell 2020,
E: stemcellcongress@geneconferences.com
Tel: (+44) 2037691755
What's App: (+44) 1403582077

7 Conference Session Themes:
- Novel Engineering and Discovery Strategies
- ADCs/Antibody-Drug Conjugates
- Bispecific Antibodies and Multi-Functional Biologics
- Immuno-Oncology
- Preclinical and Clinical Case Studies
- Delivery Strategies and Crossing/Penetrating Biological Barriers
- Engineering Strategies for TCR and CAR T Cell Therapies

This year's summit will take a deeper look at:

Walk away with a blueprint for more accurate, more efficient and more effective RandD processes.

Event Information: DDTSS Webinar: Nonclinical Safety Strategies for Gene Therapy

Date and time: Tuesday, February 25, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)

Duration: 1 hour

Description: Gene therapy has been a hot topic these recent years, with the first approvals allowing patients to be successfully treated. This increased interest in gene therapy resulted in a lot of potential therapies in preclinical and clinical development.
This webinar will cover the basis of what gene therapy is and the main toxicology concerns and considerations that need to be investigated when developing a nonclinical safety package.
Presenters:
Timothy Maclachlan, Executive Director, PCS TA Head, New Indications Discovery Unit, Novartis
Kelly Flagella, Executive Director Toxicology at Ultragenix

Registration is required.

Attendee Link

Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.

Despite the lack of clinical trial success, new investments are being made in forward-thinking biotechs, digital and blood-based biomarker technologies are advancing, new targets are emerging, and gene therapy is taking the limelight.

Don’t miss your opportunity to join over 150 fellow CNS experts from Biogen, AbbVie, Sanofi and more, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.

Venue Details: Hyatt Regency Boston, 1 Avenue de Lafayette, Boston, MA, 02111, United States

Target Audience:

• Academic, industry and government researchers engaged in developing therapeutic approaches and medical countermeasures (MCMs) against ocular pathologies resulting from exposure to chemical toxicants
• Government stakeholders and funding agencies

Objectives of the Scientific Meeting:

• Development of MCMs that mitigate acute and chronic corneal manifestations in response to ocular toxicants relies on the development of well-characterized experimental models with defined pathophysiology that allow for effective bridging to humans. Such models are also essential to demonstrate therapeutic efficacy.
• This meeting will bring together subject matter experts from the civilian and military research communities to discuss the current state of the field, including potential therapeutic approaches and available models.
• Attendees of the workshop will contribute to our understanding of pathologies and models available for studying toxic ocular injuries and their utility in the research and development of therapeutics. Most importantly, the workshop will address current knowledge gaps to identify possible refinements or new directions to advance MCM development.

Session Topics:

• Acute and Chronic Responses to Corneal Toxicity
• Mechanistic Basis of Corneal Pathophysiologies and Wound Healing
• Therapeutically Accessible Models of Corneal Toxic Injury
• Therapeutic Approaches to Mitigate Corneal Pathophysiologies
• Current Research/Development Perspectives and Resources for Researchers
• Meeting Wrap Up

Organizers:

• National Eye Institute (HHS/NIH/NEI)
• U.S. Army Medical Research Institute for Chemical Defense (DoD/USAMRICD)
• National Institute of Allergy and Infectious Diseases (HHS/NIH/NIAID)

Opportunities for travel awards, oral and/or poster presentations are available - see

Endorsement: Education and Career Development Committee (ECDC), Graduate Student Leadership Committee (GSLC), Women in Toxicology (WIT)

This webinar will feature experienced faculty members who can provide input on mentoring issues and how to seek advice throughout your career, even as you transition to independence. The primary learning objectives will be: (1) How to maintain mentoring relationships during the transition to independence, especially while trying to distinguish yourself from your mentor/PI. (2) How to become a good mentor—while still junior yourself—as you build your lab and advise others from the role of PI. Moderator-led discussion will feature perspectives from three academic career stages (graduate student, postdoc, assistant professor).

Debra Laskin, PhD
Rutgers University

Registration is required.

In this webinar, our first presenter, Lois Haighton (board certified toxicologist and Director in the Food & Nutrition Group of Intertek Scientific & Regulatory Consultancy), will discuss the current data relating to the safety of cannabis to provide a framework for understanding what is currently known regarding inhaled and ingested cannabis products and what safety concerns still exist. Our second presenter, Garrett Graff (Managing Attorney at Hoban Law Group, and nationally recognized as a Cannabis Law Trailblazer by the National Law Journal), will discuss the legal and regulatory background for cannabis use in Canada and the US.

With three events in one, we encourage conversation so you can inspire change, champion innovation, and address complex challenges that the biologics industry is facing. Together, we're improving patient health.

Save 15% off your congress pass with the code Evvnt15.

Invitation

Dear Colleagues,
On behalf of Beni- Suef University, Egypt, we are delighted to invite all scientists from academia and industry and representatives of national and international agencies, to attend the International conference: Environmental Pollution Risks in Developing Countries (EPRDC 2020)
Under the Patronage of:
Prof. khaled Abdul Ghaffar –Minister of Higher Education and Scientific Research
Prof. Mansour Hasan- President , Beni - Suef University
Prof. Badr Nabeh, Vice President, Beni Suef University
Prof. Khaled Abbas Helmy Abdou General Secretary, Beni Suef University

Conference theme:

Environmental pollution risks in developing countries (EPRDC 2020)
?????? ?????? ??????? ?? ??????? ???????
3 – 4 MARCH, 2020 - Beni Suef University, Egypt

Objectives:
1. Exchange the state of the art on climate change and environmental sciences.

2. Gathering scientific information and experiences in order to identify the common and urgent environmental issues in developing countries.

4. Exchange the knowledge related to the new green technology aspects.

Topics:
1- Environmental pollution.

3-Innovative technologies of environmental monitoring.
4-water quality and wastewater management .
5- Environmental pollution and food safety.
6- Renewable energy.
7- Waste management and sustainability.
8- Green chemistry
9- Climate changes and environmental hazards.
The organizers of the International Symposium on environmental pollution risks in developing countries (EPRDC 2020) promise to prepare a balanced programme including oral presentations workshops, , interactive seminars and nice social events.
We are looking forward to meeting you again in Egypt

• Registration and payment information:
Fee:
Participant
category Early registration Late registration
Egyptians
(LE) Non Egyptians
($) Egyptians
(LE) Non Egyptians
($)
Non-Bsu Participants 300 300 350 350
BSU- members 150 150 200 200
Student 100 100 150 150

- Payment by cash to the Beni- Suef University (9/450/87972/7).
- Deadlines
1-Early registration:31 December 2019.
2- submission of abstracts and late registration : 15 February 2020

Guidelines for submission
Poster submission :
Please ensure your poster does not exceed the poster board dimensions; 75 cm wide x 100 cm high
Oral submission:
Microsoft power point or PDF
Abstract submission
Font size 12, Normal, Times New Roman, 1.5 space
• Official languages: English- Arabic
Contact us:

Conference Secretary:
- RAGAA AZZAT : 01002679489
- DALIA ELFOULY: 01068813441
- Amro Mohamed : 01000086960

Get in touch :
Web site : www.eprdc2020. bsu .edu.eg
Face book: https://www.facebook.com/EPRDC2020
EMAIL : eprdc2020@bsu.edu.eg

Speaker
Dr. Charles Geraci
Associate Director of Emerging Technologies
National Institute for Occupational Safety and Health (NIOSH/CDC)

Travel Grants for Trainees available

Early bird registration deadline: December 13, 2019

Call for Poster Deadline: January 31, 2020

Keynote Addresses

Linda Birnbaum PhD, NIEHS director (retired)

Dean P Jones PhD, Emory University

visit

Quality content. The agenda is packed with carefully selected talks on topics as diverse as the challenges you face.

Tailor your experience. 4 parallel streams give you the chance to personalise your agenda and delve deep into the topics pertinent to your challenges. Choose from Small Molecules, Biologics, Technology And Innovation or Device Development.

Key themes for 2020 include:

With scarce treatment options leaving inborn errors of metabolism a devastating, unfilled and unmet medical need, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy, safety and commercial viability.

This is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism.

Obesity-2020 conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations.

The theme of the Conference is “Science and education for action against HPV”. Through workshops, lectures, oral and poster sessions presenting the latest research results, the program will cover papillomavirus (PV)-related topics from basic science to global health impact. We will be paying special attention to HPV prevention and control in populations that are most vulnerable to HPV disease worldwide, including those in Low- and Middle-Income Countries.

Our overarching theme will be harnessing the power of innovation from HPV research to deliver global prevention and control of HPV-related disease.

See you at IPVC 2020!

As phage therapy offers an opportunity to tackle the ever-growing problem of antibiotic resistant infections, the 2nd Bacteriophage Therapy Summit returns to not only drive forward the translation of phage pharmacology into the clinic but also generate discussion around the direction that phage therapy is heading and how this can be commercialized and delivered into the hands of physicians and patients in need.

With a clear focus on overcoming the translational and development challenges of this re-emerging therapeutic class, join your peers to be part of the discussion to facilitate the translation of phage products into targeted, clinically successful therapeutics.

The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.

Incorporating insights from 80+ industry-leading speakers, this conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.

This is your comprehensive guide to define your commercial path forward in 2020.

A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance

Sponsored by Scynexis

CO-CHAIRS FOR 2020: Cara Cassino, Chief Medical Officer, Contrafect and Michael Dawson, Director, Mike Dawson Antimicrobial Research Consultancy

As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.

This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.

It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.

Event Hashtag: #SMiBugs

Join 2000+ pharma decision-makers and healthcare innovators to:

Why you need to attend:

-9 dedicated conference streams: Barcelona is huge – 2000+ people in total. Yet it’s also intimate, tailored just for you. You’ll spend most of the conference in one of 9 tracks with sessions that hit all your buttons.
- All stakeholders. All functions. 1 place: The most cross-functional pharma event in the world – executives from marketing, commercial, sales, market access, medical affairs, patient engagement, RWE, IT, clinical and more.
- More than just conference sessions: Sometimes, the best ideas don’t come from the stage. They come from those chance happenings when you joined a roundtable or went to a networking evening.

Venue Details: Centre de Convencions Internacional de Barcelona, 11-14 Plaça de Willy Brandt, Barcelona, 08019, Spain

Once again, the conference will bring together the leading microbiome companies working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond. Expanding on this core focus year on year, we continue to offer informative, hands-on workshops, panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond the usual infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.

Toxicology Congress 2020 provides a global Platform to the toxicologists, pharmacologists, PhD Scholars, medical and Pharmacy Students, Academicians (professors), researchers and lab experts to share their research findings in the field of Toxicology and Pharmacology. It provides an excellent opportunity for Toxicology and Pharmacology industries and companies to display their products and services in the said field at our exhibitors’ desk to gain global recognition to their products and services offered. Join us at this prestigious event.

Over 300 pharmaceutical scientists working across formulation, drug delivery and manufacturing science and technologies, representing global pharmaceutical organisations, leading biotech and internationally renowned academic institutions

PLUS interactive opportunities including:
- Roundtable discussions
- Panel discussions
- Pre-event podcasts and webinars

Co-located with the 3rd Annual Inhalation and Respiratory Drug Delivery USA Congress.

Go Social: Join our Formulation and Drug Delivery Network on LinkedIn, follow us on Twitter @FDDCongress and join the conversation at #FDDUK20

*2020 Live Webinar*

CHAIRED BY: Lynne Ensor,VP Technical, Parexel

Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, explore data integrity considerations for conventional and rapid microbiology methods, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.

Post-Conference Workshop – May 1, 2020
The Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET)
Workshop Leader: Veronika Wills, Manager, Technical Services, Associates of Cape Cod

Prices:
Conference + 1 Workshop: USD 2498.00
Conference Only: USD 1999.00
Workshop Only: USD 499.00

Time: 8:30 am to 5:00 pm

Join over 80 speakers and 300 attendees across 4 days of unrivalled depth and breadth of discussion broken down into:
- 4 tracks hosting scientific case studies and thought leading panel analysis of discovery, translational and clinical drug development, and non-invasive biomarker application in the clinical algorithm of care
- 7 discussion driven, expert led workshops into: epigenetics, targeting the inflammasome, assessing translational models and non-invasive evaluations of NAFLD and NASH; understanding NASH associated-hepatocellular carcinoma, drug safety in NASH, and regulatory and clinical considerations for paediatric NASH
- 2 forward thinking seminars dedicated to applying relationships and lessons learned from wider anti-fibrotic drug development for pulmonary, renal and cardiac fibrosis to hepatic fibrosis, and understanding the market access challenges associated with NASH including the pricing and reimbursement considerations

This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.

Join SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

Successfully Validate Novel Targets, Improve Preclinical Predictability of Patient-Derived Models and Optimize Drug Pharmacology to Accelerate Translation of Robust Protein Misfolding Targeted Therapeutics into the Clinic. With numerous molecular approaches emerging that demonstrate viable efficacy of targeting protein misfolding and aggregation, join the Protein Misfolding Drug Discovery Summit – the only industry and translational focused conference dedicated to the discovery and translation of disruptive disease-modifying therapeutics with optimized pharmacology to target protein misfolding in proteopathies and cancer.

Venue Details: Revere Hotel Boston Common, 200 Stuart Street, Boston, MA, 02116, United States

The unique scientific program of the Congress will bring you the latest updates in the field of autoimmune diseases, presented by the world's leading experts, while at the same time providing an amazing stage for young upcoming talents to present their research to a first-rate audience.

Established by Professor Yehuda Shoenfeld, the congress constitutes a network of international leaders on immunology, rheumatology and related fields, all of whom contribute their unique and diverse knowledge to the "family of autoimmunity."

SLAS Europe 2020 provides a unique combination of education, access to innovative technologies and intelligent peer networking, delivering unmatched value for professionals and students looking to discover the latest life sciences technologies and how they can be applied to drive research objectives.

This year, the symposium will be held on the Penn State University campus in State College, PA from June 14-18, 2020. The sessions will showcase cutting edge research and highlight advancements in the study of AHR in terms of public and environmental health, toxicology, pharmacology and biology of development. The themes of the symposium will therefore address many systems / models of pathologies related to environmental toxicology.

Along with opportunities to network with colleagues from around the world and learn the latest scientific information, the Penn State campus and surrounding area offers many things to do and see. Central Pennsylvania is a beautiful part of the United States boasting scenic mountains, local culture, and a world class research institution. Come for the meeting, but make sure to take advantage of all the area has to offer.

Across 3 days, with 100+ ADC experts, this comprehensive antibody-drug conjugate conference will enable you to propel your ADC pipeline into clinical development. Some of the highlights from the 2020 meeting include exploring targets beyond HER-2; confidently meeting Chinese NMPA regulatory requirements to successfully translate into the clinic and effectively scaling up your manufacturing processes for clinical development. World ADC Asia not only delves into general antibody-drug conjugate challenges, it also focuses on challenges and opportunities specific to development within Asia.

Don’t miss your opportunity to:
* Hear the rationale for submitting INDs in different countries; how to leverage the strength of Asia and US/Europe with the NMPA, BlissBio and Shanghai Miracogen
* Form lasting connections by engaging directly with 100+ attendees from the leading companies actively developing ADCs in Asia, such as Daiichi Sankyo, Bio-Thera, Sumitomo Dainippon Pharma Co, Seattle Genetics and Mersana
* Learn from the leading Chinese biotech’s who have recently submitted INDs or entered the clinic including Shanghai Miracogen, Blissbio and Genequantum

Venue Details: Hilton Tokyo Bay, 1-8 Maihama, Urayasu, Chiba, 279-0031, Japan

To explore foremost research in pharmaceutical sciences and to discuss clinical, analytical and commercial issues in pharmacology, Pages Conferences is organizing Global Conferennce on Pharmaceutics and Pharmacology, which will be held during August 06-07,2020 in San Antonio. The conference offers a seamless view of the industry today while paving way for future research.

The conference aims to empower future generations in different fields of pharmaceutics to explore exciting research outcomes that lie in tune with the objectives and theme of this exciting event. It further helps you enhance your understanding of commercial, scientific and regulatory issues that affect strategic decision making in the pharmacology sector.

Sessions Link: https://pagesconferences.com/pharmacology-pharmaceuticsconference/call-for-abstracts.php

Contact us:

Julie Andrieo
gcpp-2020@pagesconferences.com

To provide critical information and knowledge based on latest research in toxicology, Scientific Federation is organizing the Global Conference on Toxicology which is scheduled to be held during August 06-07,2020, in San Antonio, USA. The aim of this conference is to share critical toxicology information to protect public health.

For more information:

Satya | Program Manager
Toxicology-2020
gct-2020@pagesconferences.com

Abstract submission deadline: March 31, 2020

Early registration deadline: May 14, 2020

Every year we see innovation and breakthroughs at every level of drug development.

Covering both small molecules and biologics, you'll find new technologies, concepts and case studies in areas such as...